Substances that are recognized by the immune system and induce an immune reaction.
DrugDrug NameDrug Indication
DB00109EnfuvirtideEnfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.
DB04933EritoranInvestigated for use/treatment in sepsis and septicemia.
DB05006AdecatumumabInvestigated for use/treatment in breast cancer and prostate cancer.
DB05299keyhole limpet hemocyaninInvestigated for use/treatment in bladder cancer and solid tumors.
DB05413TifuvirtideInvestigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection.
DB05793PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
DB05942GI-5005Investigated for use/treatment in hepatitis (viral, C).
DB06447E5531Investigated for use/treatment in sepsis and septicemia.
DB06495OnerceptInvestigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease.
DB06611PegsunerceptInvestigated for use/treatment in rheumatoid arthritis.
DB11253Xanthan gumNot Available
DB11377BambermycinsNot Available
DB11601Tuberculin Purified Protein DerivativeIndicated as a diagnostic agent in Mantoux Test used to detect infection with *Mycobacterium tuberculosis*.
DB11831DinitrochlorobenzeneNot Available
DB13889Meningococcal polysaccharide vaccine group ANot Available
DB13890Meningococcal polysaccharide vaccine group CNot Available
DB14141p-PhenylenediamineNot Available
DB11627Hepatitis B Vaccine (Recombinant)Active immunization against hepatitis B virus infection. The vaccine will not protect against infection caused by hepatitis A and non-A non-B hepatitis viruses. As hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection or carrier state, it can be expected that hepatitis D will also be prevented by vaccination with hepatitis B virus vaccine. The vaccine can be administered at any age from birth onwards. It may be used to start a primary course of vaccination or as a booster dose. It may also be used to complete a primary course of vaccination started with plasma-derived or yeast-derived vaccines or as a booster dose in subjects who have previously received a primary course of vaccination with plasma-derived or yeast-derived vaccines. In areas of low prevalence of hepatitis B, vaccination is strongly recommended in subjects who are at increased risk of infection. These include the following groups: * Health professionals: physicians and surgeons; oral surgeons and dentists; nurses, dental nurses, dental hygienists, podiatrists; IV teams and operating room personnel; paramedical personnel in close contact with patients; staff in hemodialysis, nephrology, hepatology, hematology and oncology units; laboratory personnel handling blood and other clinical specimens; blood bank and plasma fractionation workers; pathologists and morgue attendants; cleaning staff who handle waste in hospitals; emergency and first aid workers; ambulance staff; dental, medical and nursing students. * Patients: patients receiving frequent blood transfusion or clotting factor concentrates, such as those in oncology units and those with thalassemia, sickle-cell anemia, cirrhosis, hemophilia, etc.; patients on hemodialysis; patients with type 2 diabetes. * Personnel and residents of institutions: persons with frequent and/or close contacts with high-risk groups; prisoners and prison staff; residents and staff of institutions for the developmentally challenged (those who are in contact with aggressive biting residents being at highest risk). * Persons at increased risk due to their sexual practices: males having sexual contact with other males; others with multiple sexual partners or with a recent history of sexually transmitted disease. * Persons who use injectable drugs illicitly. * Travellers to areas of high endemicity and their close contacts. * Household contacts of any of the above groups and of patients with acute or chronic hepatitis B infection. * Infants born of HBsAg-positive mothers. * Chronic Liver Disease (CLD): subjects with chronic liver disease; subjects at risk of developing CLD (e.g. Hepatitis C virus carriers, persons who abuse alcohol). * Others: police; fire fighters; armed forces personnel; morticians and embalmers; those who through their work or personal lifestyle may be exposed to the hepatitis B virus. * In areas of both low and high prevalence, vaccination should be offered to all young children and neonates at risk, as well as to adult high risk groups.
DB15015Recombinant CD40-ligandNot Available
DB15081Melanoma antigen recognized by T-cells 1Not Available
DB15160AsunerceptNot Available
DB15301BevifimodNot Available